Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.58 |
| ▸ | JAK1 | P23458 | 2/20 | 0.58 |
| ▸ | JAK3 | P52333 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 4/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655942 | 0.85 | JAK3 (0.45) | MAPK1JAK2JAK1JAK3KDM4E | |
| SCHEMBL2484874 | 0.84 | MAPK1 (0.56) | MAPK1JAK2JAK1JAK3SYK | |
| SCHEMBL1369859 | 0.82 | JAK3 (0.63) | MAPK1JAK2JAK1JAK3SYK | |
| SCHEMBL1370244 | 0.79 | JAK3 (0.64) | MAPK1JAK2JAK1JAK3SYK | |
| SCHEMBL14655948 | 0.78 | PAK1 (0.47) | JAK2JAK1JAK3 | |
| SCHEMBL1352558 | 0.77 | JAK3 (0.54) | MAPK1JAK2JAK1JAK3SYK | |
| SCHEMBL21592449 | 0.77 | MAPK1 (0.64) | MAPK1JAK2JAK1JAK3SYK | |
| SCHEMBL12332949 | 0.77 | JAK3 (0.62) | MAPK1JAK2JAK1JAK3SYK | |
| SCHEMBL12299968 | 0.77 | JAK3 (0.62) | MAPK1JAK2JAK1JAK3SYK | |
| SCHEMBL2378085 | 0.77 | JAK3 (0.62) | MAPK1JAK2JAK1JAK3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | claimed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2571881-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | claimed |
| CN-103003281-A | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | claimed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | claimed |
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | claimed |
| CN-102803265-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2012-11-28 | — | — | CN | claimed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2571881-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| CN-103003281-A | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| CN-102906095-A | Pyrrolopyrazine derivatives as SYK and JAK inhibitors | HOFFMANN LA ROCHE | 2013-01-30 | — | — | CN | disclosed |
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| CN-102803265-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2012-11-28 | — | — | CN | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | MAPK1 438/4885JAK2 3/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.